Artax Biopharma, Inc.

Artax Biopharma's AX-158 Demonstrates Clinical Validation in Phase 2a Psoriasis Trial

8 months ago

• Artax Biopharma's AX-158, a first-in-class oral Nck modulator, has achieved clinical validation in a Phase 2a trial for psoriasis, showcasing a novel approach to autoimmune disease treatment. • The Phase 2a study demonstrated statistically significant improvements in T cell and psoriasis-related biomarkers, aligning with observed PASI improvements in patients with mild to moderate plaque psoriasis. • AX-158 exhibited a well-tolerated safety profile in the trial, with no reported infections or discontinuations, reinforcing its potential as a safe and effective treatment option. • Further studies in other autoimmune diseases, such as atopic dermatitis, are planned, with clinical results anticipated by the end of 2026, expanding the potential applications of Nck modulation.